Your browser doesn't support javascript.
Cyclic 68Ga-Labeled Peptides for Specific Detection of Human Angiotensin-Converting Enzyme 2.
Parker, Matthew F L; Blecha, Joseph; Rosenberg, Oren; Ohliger, Michael; Flavell, Robert R; Wilson, David M.
  • Parker MFL; Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.
  • Blecha J; Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.
  • Rosenberg O; Department of Medicine, University of California, San Francisco, San Francisco, California; and.
  • Ohliger M; Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.
  • Flavell RR; Department of Radiology, Zuckerberg San Francisco General Hospital, San Francisco, California.
  • Wilson DM; Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.
J Nucl Med ; 62(11): 1631-1637, 2021 11.
Article in English | MEDLINE | ID: covidwho-1496930
ABSTRACT
In this study, we developed angiotensin-converting enzyme 2 (ACE2)-specific, peptide-derived 68Ga-labeled radiotracers, motivated by the hypotheses that ACE2 is an important determinant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) susceptibility and that modulation of ACE2 in coronavirus disease 2019 (COVID-19) drives severe organ injury.

Methods:

A series of NOTA-conjugated peptides derived from the known ACE2 inhibitor DX600 were synthesized, with variable linker identity. Since DX600 bears 2 cystine residues, both linear and cyclic peptides were studied. An ACE2 inhibition assay was used to identify lead compounds, which were labeled with 68Ga to generate peptide radiotracers (68Ga-NOTA-PEP). The aminocaproate-derived radiotracer 68Ga-NOTA-PEP4 was subsequently studied in a humanized ACE2 (hACE2) transgenic model.

Results:

Cyclic DX-600-derived peptides had markedly lower half-maximal inhibitory concentrations than their linear counterparts. The 3 cyclic peptides with triglycine, aminocaproate, and polyethylene glycol linkers had calculated half-maximal inhibitory concentrations similar to or lower than the parent DX600 molecule. Peptides were readily labeled with 68Ga, and the biodistribution of 68Ga-NOTA-PEP4 was determined in an hACE2 transgenic murine cohort. Pharmacologic concentrations of coadministered NOTA-PEP (blocking) showed a significant reduction of 68Ga-NOTA-PEP4 signals in the heart, liver, lungs, and small intestine. Ex vivo hACE2 activity in these organs was confirmed as a correlate to in vivo results.

Conclusion:

NOTA-conjugated cyclic peptides derived from the known ACE2 inhibitor DX600 retain their activity when N-conjugated for 68Ga chelation. In vivo studies in a transgenic hACE2 murine model using the lead tracer, 68Ga-NOTA-PEP4, showed specific binding in the heart, liver, lungs and intestine-organs known to be affected in SARS-CoV-2 infection. These results suggest that 68Ga-NOTA-PEP4 could be used to detect organ-specific suppression of ACE2 in SARS-CoV-2-infected murine models and COVID-19 patients.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Peptides, Cyclic / Gallium Radioisotopes / Angiotensin-Converting Enzyme 2 Type of study: Cohort study / Observational study / Prognostic study Limits: Animals Language: English Journal: J Nucl Med Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Peptides, Cyclic / Gallium Radioisotopes / Angiotensin-Converting Enzyme 2 Type of study: Cohort study / Observational study / Prognostic study Limits: Animals Language: English Journal: J Nucl Med Year: 2021 Document Type: Article